Literature DB >> 3132380

In vitro activity of temafloxacin, a new difluoro quinolone antimicrobial agent.

N X Chin1, V M Figueredo, A Novelli, H C Neu.   

Abstract

Temafloxacin, a new difluoro quinolone, inhibited the majority of Enterobacteriaceae at less than or equal to 1 microgram/ml. It was 4-8-fold less active than ciprofloxacin and 2-fold less active than ofloxacin. Cefotaxime and imipenem-resistant isolates such as Enterobacter cloacae, Citrobacter freundii, Pseudomonas aeruginosa, and Acinetobacter spp. were inhibited. Temafloxacin inhibited Neisseria, Branhamella, and Haemophilus species at less than 0.25 microgram/ml. Methicillin-susceptible and methicillin-resistant Staphylococcus aureus, Staphylococcus epidermidis and Clostridium spp. were inhibited at concentrations less or equal to that of ciprofloxacin and ofloxacin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3132380     DOI: 10.1007/bf01962176

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  3 in total

1.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

2.  Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.

Authors:  D J Hardy; R N Swanson; D M Hensey; N R Ramer; R R Bower; C W Hanson; D T Chu; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

3.  Factors influencing the in vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620.

Authors:  L Hirschhorn; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

  3 in total
  17 in total

1.  Effects of 2 quinolone antibacterials, temafloxacin and enoxacin, on theophylline pharmacokinetics.

Authors:  F Sörgel; G Mahr; G R Granneman; U Stephan; P Nickel; P Muth
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

2.  In vitro activity of sparfloxacin.

Authors:  N X Chin; J W Gu; K W Yu; Y X Zhang; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  Activity of temafloxacin against respiratory pathogens.

Authors:  R N Swanson; D J Hardy; D T Chu; N L Shipkowitz; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

4.  Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.

Authors:  H P Endtz; J W Mouton; J G den Hollander; N van den Braak; H A Verbrugh
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  Comparative in vitro activity of the new fluoroquinolone BMY-40062.

Authors:  N X Chin; H Neu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-08       Impact factor: 3.267

6.  In vitro activities of lomefloxacin and temafloxacin against pathogens causing diarrhea.

Authors:  J Segreti; J A Nelson; L J Goodman; R L Kaplan; G M Trenholme
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

7.  Use of a broad-host-range gyrA plasmid for genetic characterization of fluoroquinolone-resistant gram-negative bacteria.

Authors:  P Heisig; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

8.  Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients.

Authors:  K V Rolston; D H Ho; B LeBlanc; G Gooch; G P Bodey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-10       Impact factor: 3.267

Review 9.  Pharmacokinetics of temafloxacin after multiple oral administration.

Authors:  G R Granneman
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

10.  Pharmacokinetics of temafloxacin in patients with liver impairment.

Authors:  G R Granneman; G Mahr; C Locke; P Nickel; W Kirch; W Fabian; M Kinzig; K G Naber; F Sörgel
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.